Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Daily News

INOCA May Be at the Root of Angina for Many Long-COVID Patients

Caitlin E. Cox

April 17, 2024

News Daily News

Drugs to Tweak RAAS Response No Help in Acute COVID-19, RCTs Show

Caitlin E. Cox

April 19, 2023

News Daily News

Flu Vaccines Reduce MACE, Especially in ACS: Meta-analysis

Yael L. Maxwell

May 06, 2022

News Conference News ISC 2022

Ischemic Stroke Risk Highest Early After COVID-19 Diagnosis

Todd Neale

February 17, 2022

Presentation ESC 2021

Continuing versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers:Impact on Adverse Outcomes in Hospitalized Patients with Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2

Presenter: Renato D. Lopes

August 30, 2021

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

News Opinion CV Team Dispatch

January 2021 News Roundup

L.A. McKeown

January 01, 2021

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News Daily News

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

Shelley Wood

June 11, 2020

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Caitlin E. Cox

April 23, 2020

News Daily News

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

Todd Neale

April 10, 2020

News Daily News

ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice

Yael L. Maxwell

March 26, 2020

News Daily News

Could RAS-Inhibitor Prescription After TAVR Improve 1-Year Outcomes?

Yael L. Maxwell

December 10, 2018

News Daily News

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

Shelley Wood

March 29, 2018

News Daily News

Acute MI Quality Improvement Program Fails in India, but Researchers See Bright Side

L.A. McKeown

February 15, 2018

News Daily News

Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure

Michael O'Riordan

January 19, 2016

News Daily News

Medicare Part D Has Scant Effect on Outcomes for Acute MI Patients

Yael L. Maxwell

November 04, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

Advertisement

INOCA May Be at the Root of Angina for Many Long-COVID Patients

Drugs to Tweak RAAS Response No Help in Acute COVID-19, RCTs Show

Flu Vaccines Reduce MACE, Especially in ACS: Meta-analysis

Ischemic Stroke Risk Highest Early After COVID-19 Diagnosis

Continuing versus Suspending Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers:Impact on Adverse Outcomes in Hospitalized Patients with Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

January 2021 News Roundup

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

New Wuhan Data Confirm High Hypertension Rate in COVID-19 Deaths

ACE Inhibitors, ARBs, and COVID-19: New Insights, Advice

Could RAS-Inhibitor Prescription After TAVR Improve 1-Year Outcomes?

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

Acute MI Quality Improvement Program Fails in India, but Researchers See Bright Side

Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure

Medicare Part D Has Scant Effect on Outcomes for Acute MI Patients

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content